ENGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
enGene Therapeutics Inc (ENGN) is not a good buy for a beginner investor with a long-term strategy at this time. The stock faces significant challenges, including negative analyst sentiment, disappointing trial data, and a lack of positive trading signals. While the company has sufficient cash reserves to support R&D, the broader outlook remains uncertain, and the stock lacks clear catalysts for growth in the near term.
The technical indicators show a neutral trend with no clear buy or sell signals. The MACD is positive but contracting, RSI is neutral at 48.341, and moving averages are converging. The stock is trading near its pivot point of 1.69, with resistance at 1.786 and support at 1.595.
The company has $285.17 million in cash and marketable securities, providing operational flexibility for ongoing clinical trials and R&D. There is potential for pivotal data from the LEGEND trial in the second half of 2026.
Analysts have downgraded the stock significantly, citing disappointing trial data and reduced confidence in the competitive profile of detalimogene. The stock has seen a consistent decline in price targets, and investor sentiment remains cautious. No recent congress trading data or insider buying trends were observed.
The company reported a net loss of $30.23 million for Q2 2026, wider than the previous year's loss due to increased operating expenses. Operating expenses for Q2 2026 were $32.0 million, reflecting ongoing investments in R&D and marketing.
Analysts have downgraded the stock multiple times, with price targets significantly reduced. Morgan Stanley, UBS, Oppenheimer, and others have expressed concerns about the competitive profile of detalimogene and the lack of near-term catalysts. The general sentiment is negative, with a 'show-me' approach dominating investor outlook.
